Assessing User Fees Under the Prescription Drug User Fee Amendments of 2017; Guidance for Industry; Availability

Summary

The Food and Drug Administration (FDA) has released a final guidance for industry on assessing user fees under the Prescription Drug User Fee Amendments of 2017 (PDUFA VI), which implements changes to policies and procedures for the agency's application process.